GSK.L GSK plc
Company Analysis
Latest News
GSK Wins FDA Approval for Hepatitis B Therapy With Cure Potential
The U.S. Food and Drug Administration (FDA) approved GSK’s Hibsago (bepirovirsen) to treat chronic hepatitis B (CHB) in certain adults. The first-in-class...
GSK Wins First Immunotherapy Approval for Jemperli in Rectal Cancer
The U.S. Food and Drug Administration (FDA) granted accelerated approval to GSK’s Jemperli (dostarlimab) for adults with stage II or III locally advanced...
GSK reports 61% response rate for Ris-Rez in global lung cancer study
GSK reported positive first global data for its investigational antibody-drug conjugate, risvutatug rezetecan (Ris-Rez), in patients with relapsed...
GSK to Cut Up to 1,217 Belgian Jobs in £1.9 Billion Restructuring
GSK plans to cut up to 1,217 jobs in Belgium as part of a broader global restructuring. The proposed reductions will primarily affect management and other...
GSK to Invest Over $800 Million in Pennsylvania Hub, Add 300 Jobs
GSK plc plans to invest more than $800 million to expand its Upper Merion, Pennsylvania, site into a biopharmaceutical manufacturing and research hub. The...
GSK's ViiV Reports Cabenuva Beats Daily HIV Pills in Phase IIIb Trial
ViiV Healthcare, the HIV-focused company majority-owned by GSK, said its long-acting injectable treatment Cabenuva met the primary endpoint in the Phase IIIb...
🟢 GSK is trading 4.15% up today on positive lung-cancer trial results
GSK is trading at £1844.00 (+4.15%) after positive lung-cancer trial data strengthened its oncology growth outlook. • Jideytro delivered a 94% objective...
GSK Jideytro Hits 94% Response Rate, Aiming for First-Line FDA Approval
GSK reported positive results from its ARROS-1 trial for the lung cancer drug Jideytro (zidesamtinib). The data, presented at the 2026 World Conference on Lung...
GSK targets oncology to offset HIV patent cliff, raises $6.5 billion
GSK management outlined a long-term turnaround strategy at Bernstein’s 23rd Annual Pan-European Strategic Decisions Conference. The plan focuses on...
GSK Wins First-Ever Global Approval for Hepatitis B Drug in Japan
GSK announced it has received its first global regulatory approval for Hibsago (bepirovirsen) in Japan. The drug is the first and only approved treatment in...
GSK Licenses Chugai Antibody, Targeting Global Dengue Fever Solutions
GSK plc signed an exclusive global licensing agreement with Japan-based Chugai Pharmaceutical Co Ltd. GSK acquired the rights to develop, manufacture, and...
GSK India Profit Jumps 15.7%, Driven by Vaccine and Medicine Growth
GlaxoSmithKline Pharmaceuticals Ltd. reported a consolidated net profit of ₹237.18 crore for the quarter ending June 30, 2026. This figure represents a 15.7%...
GSK Beats Q2 Estimates, Launches £1.9 Billion Cost-Saving Program to Fund R&D
GSK plc reported second-quarter earnings that surpassed analyst expectations, with turnover reaching £8.41 billion. The strong performance was driven by its...
GSK’s Bone Cancer Drug Hits Trial Goal, Marking Second Phase III Win
Hansoh Pharma announced that its experimental antibody-drug conjugate, risvutatug rezetecan (Ris-Rez), met the primary goal in a late-stage osteosarcoma trial....
🟢 GSK surges 4% today on FDA approval of lung cancer drug Jideytro
• GSK is trading 4% up at £2040.00 today, following the US FDA's approval of its lung cancer drug, Jideytro. • The approval marks a major milestone in GSK's...
GSK Scraps $2 Billion Cough Drug Camlipixant, Citing Mixed Trial Results
GSK terminated development of camlipixant for refractory chronic cough (RCC). The decision follows mixed outcomes from the CALM-1 and CALM-2 Phase 3...
GSK hits survival goal in world-first lung cancer drug trial
GSK announced Friday that its licensed cancer therapy, risvutatug rezetecan (Ris-Rez), met its primary endpoint of overall survival in a pivotal Phase 3 trial....
GSK wins Canada approval for Exdensur, first twice-yearly respiratory biologic
Health Canada approved GSK’s Exdensur (depemokimab) for two distinct respiratory indications. The drug serves as an add-on maintenance treatment for severe...
GSK and Spero Win FDA Approval for Utebzi, First Oral Carbapenem Antibiotic
The FDA approved GSK and Spero Therapeutics’ Utebzi (tebipenem pivoxil) for adult complicated urinary tract infections. This oral antibiotic treats cUTIs and...